Australia’s CRO for biotechs, Avance Clinical, deep dives into the patient recruitment landscape identifying the mechanisms and processes that deliver exceptional patient recruitment for early phase trials in Australia.
Avance Clinical also offers models for later phase pivots to large patient populations in Central and Eastern Europe and the US via exclusive collaborations with more than 3,500 sites. Learn more here.
In Australia, Site Initiation Visit (SIV) and Study Start can be achieved in 5 – 6 Weeks, plus there is up to a 43.5% refund on clinical trial spend.
Avance Clinical is the Australian-owned full-service biotech CRO that has been providing high-quality clinical research services across all phases to the US, APAC, and EU drug development industry for over 20 years.
“Our team has extensive therapeutic area knowledge and expertise and has conducted drug trials with large molecules, small molecules, gene therapies and devices providing high-quality clinical research services fit for global regulatory standards,” said Yvonne Lungershausen, Avance Clinical’s CEO
“We offer end-to-end in-house clinical research services including drug development consultation, medical writing, clinical project management, trial monitoring, pharmacovigilance, data management, statistical and pharmacokinetic services, CDISC and external and internal auditing.”